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Abstract 
Fanconi Anemia (FA) is an autosomal reces-
sive  disease  characterized  by  chromosome
instability,  cellular  hypersensitivity  to  DNA
cross-linking agents, and increased predispo-
sition to malignancies. We describe here a 28
year-old female with FA and vaginal squamous
cell  carcinoma  treated  by  radiation  therapy
alone.  The  patient  developed  arm  phlebitis,
pulmonary fungal infection, and severe rectal
bleeding,  followed  by  hypocalcaemia,
hypokalemia,  vaginal  bacterial  and  fungal
infection,  with  subsequent  leg  and  arm
phlebitis,  perineal  abscess,  and  sepsis.  The
patient died 12 weeks later.
Introduction
Fanconi anemia (FA) is a rare cancer sus-
ceptibility syndrome with an incidence of only
1-5 per million live births in the general popu-
lation. FA is an autosomal recessive disease
characterized by chromosome instability, cellu-
lar  hypersensitivity  to  DNA  cross-linking
agents such as diepoxybutane, and increased
predisposition to malignancies. Other clinical
abnormalities associated with FA include bone
marrow  failure,  congenital  anomalies,  short
stature,  hypo-  or  hyperpigmentation  of  the
skin,  radial  ray  bone  abnormalities,  thumb
deformities, cardiac and renal anomalies and
microcephaly.1
Cytopenias in FA patients usually occur dur-
ing the first decade of life. Although the most
common  malignancies  in  FA  patients  are
hematologic, they are at increased risk of cer-
tain solid tumors, in particular squamous cell
carcinomas of the head and neck and gyneco-
logic  system.  This  susceptibility  is  due  to
mutations in the FA complementation group
genes, which encode proteins that are part of a
nuclear multiprotein core complex involved in
activating mono-ubiquitination of the FANCD2
protein during the S phase of the cell cycle and
after  exposure  to  DNA  cross-linking  agents.
The gold standard for the diagnosis of FA is the
induction  of  chromosome  fragility  by  DNA
interstrand crosslink inducing agents such as
diepoxybutane (DEB test).2 This test allows FA
to be diagnosed in patients without detectable
congenital anomalies. 
Case Report
A 28 year-old woman presented at our insti-
tution with vaginal bleeding and pelvic pain of
6 months duration. She was in generally good
health,  with  no  symptoms  such  as  fatigue,
other kinds of bleeding and recent episodes of
fever.  Physical  examination  showed  several
condilomatous like lesions in the cervix, the
right side vaginal wall and the vulva, with a 3
cm ulcerative lesion on the left vaginal wall.
She did not present with signs of bruising or
petechiae,  or  significant  cardiopulmonary
impairment.  Cervical  and  vaginal  biopsies
were performed resulting in pathological diag-
noses  of  cervical  intraepithelial  neoplasia
grade III (CIN III) and vaginal squamous cell
carcinoma  (SCC)  grade  II.  Molecular  assays
showed the presence of p53 and high-risk HPV
DNA. Laboratory workup revealed pancytopenia
(hemoglobin=8.6 g/dL, hematocrit=26.8%, leu-
cocytes=2.03¥106/mm3,  platelets=57¥106/mm3).
Magnetic  resonance  imaging  (MRI)  of  the
abdomen and pelvis showed a 4.1¥0.6¥2.5 cm
solid lesion on the distal posterior and inferior
vaginal  walls,  with  extension  to  the  left  side
(Figure 1A). The tumor was classified as a stage
II (FIGO) vaginal SCC.3 Computerized tomogra-
phy of the thorax was negative. The patient was
referred to the Hematology Department for fur-
ther examination.  High dose-rate brachythera-
py  alone  was  indicated  with  curative  intent
without  chemotherapy.  Ten  daily  fractions
were prescribed in two phases. The first, con-
sisted of 6 fractions of 5 Gy administered to the
vaginal mucosa surface and at 5 mm depth to
the tumor bed. After a 15 days interval, two
more fractions of 5 Gy each, followed by two
fractions at 4 Gy each, calculated at a 5 mm
depth were further administered as a boost to
the tumor bed. As a result, the total dose of
brachytherapy  administered  to  the  vaginal
mucosa was 30 Gy, and to the tumor, 48 Gy,
over  a  32  day  period.  Moreover,  biological
equivalent  doses  to  2  Gy  fractions  (EQD2)
were,  respectively,  37.5  Gy  to  the  vaginal
mucosa surface, 59,3 Gy to the tumor (5 mm
depth) (a/b=10), and 75.2 Gy maximum dose
at  the  anterior  rectal  wall  (a/b=3).  During
irradiation,  the  patient  experienced  mild  to
moderate  rectal  pain  and  moderate  vaginal
bleeding. A single blood transfusion was also
required due to a reduction in blood cell counts
that was observed. Following treatment, only a
residual  lesion  remained.  Afterwards,  the
patient presented with phlebitis in the arm and
a pulmonary fungal infection associated with
pancytopenia  and  required  multiple  blood
transfusions (red blood cells and platelets).
Although there were no congenital anom-
alies, FA was suspected due to cytopenias asso-
ciated with SCC at a young age. A bone marrow
biopsy  and  smear  were  compatible  with
myelodysplastic  syndrome  (MDS)  and  kary-
otyping revealed clonal cytogenetic abnormali-
ties  involving  chromosomes  11,  6  and  18.
Chromosome fragility induced by diepoxybu-
tane (DEB test) confirmed FA. Without com-
patible donors in her family, she was placed on
a waiting list for bone marrow transplantation.
Pelvic MRI performed 1 month after treat-
ment showed complete regression of disease
(Figure 1B). Two months later, however, the
patient  developed  rectal  pain  and  bleeding.
Rectoscopy showed ulceration of the anterior
rectal  wall,  with  biopsy  negative  for  tumor,
related to radiation. Subsequently, the patient
presented hypocalcaemia, hypokalemia, vagi-
nal bacterial and fungal infection, leg and arm
phlebitis,  perineal  abscess  and  sepsis.  She
died  12  weeks  after  the  initial  diagnosis  of
vaginal carcinoma, remaining hospitalized for
the last 3 weeks.
Discussion
FA patients are at 500- to 1000-fold increased
risk of developing SCC, particularly of the mucos-
al linings of the head and neck region (HNSCC),
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these patients.4 FA patients are also highly sus-
ceptible to SCCs at other anatomic sites, includ-
ing the cervix and vulva.5 There have been only
two  previous  reports  on  vaginal  cancer  in  FA
patients. In the first, two patients had vaginal
SCC preceded by Condyloma acuminatum. In the
second, involving 75 cancers in 64 FA patients,
only one patient had vaginal cancer. That patient
was treated with radiation but developed a skin
reaction  and  died  3  months  later.  Most  FA
patients whose tumors were treated with radia-
tion died shortly thereafter.6 Although radiation
therapy is the treatment of choice for patients
with advanced vaginal SCC, it should be used
cautiously in FA patients because adverse reac-
tions  to  radiotherapy  are  common  in  these
patients.  Radiosensitivity  is  associated  closely
with  the  homozygous  inheritance  of  defective
proteins  necessary  for  the  recognition  and/or
repair of DNA double strand breaks.7,8At the time
of radiotherapy, a diagnosis of FA had not been
confirmed,  and  the  patient  presented  with
pelvic/vaginal pain and vaginal bleeding with per-
sistent pancytopenia. Thererore, in an effort to
preserve her bone marrow and underlying nor-
mal tissue, besides the indication of pelvic irradi-
ation for stage II vaginal cancer, brachytherapy
alone was indicated, until a definitive diagnoses
was obtained. A total tumor dose (equivalent to 2
Gy fractions) of 59.3 Gy was prescribed to the
patient, a dose that could be considered appropri-
ate  for  tumor  control.9 A  split-course  was
planned, during which tumor response and nor-
mal tissue reaction could be observed. The max-
imum rectal dose (75 Gy) was on the range that
may increase the risk of complications, accord-
ing to the GEC-ESTRO guidelines.10However, the
tumor was located in the posterior and left later-
al walls of the lower vagina, so rectal preserva-
tion was compromised in favor of achieving bet-
ter tumor coverage, since external beam irradia-
tion was not indicated. Nevertheless, the dose
prescription depth at 5 mm (not 6 mm according
to the tumor thickness) was chosen as a rectal
tolerance dose, which did not prevent the severe
proctitis presented by the patient. It is possible
that tridimensional image-guided brachytherapy
could have provided better sparing of normal tis-
sue,  since  image-guidance  and  dose-volume
evaluations could have avoided the application of
excessive doses of radiation to the rectum and
other normal adjacent tissues. However, at the
time of this case, this technique was not avail-
able  at  our  institution.  Despite  the  doses  of
brachytherapy  applied  in  this  case  being  in
accordance with previous studies, this treatment
regimen was certainly the cause of the rectal
complications observed in the case, and did con-
tribute to the outcome of the patient. Currently,
the optimal management of hemorrhagic procti-
tis due to radiation remains unclear. However,
the maintenance of rectal doses below tolerance
limits remains the best approach to preventing
this condition. Furthermore, it is possible to treat
proctitis  with  topical  corticosteroids,  sul-
fasalazine,  mesalazin,  formalin,  argon  plasma
coagulation, laser photocoagulation, or hyperbar-
ic oxygen therapy.11 In this case, the patient died
due  to  complications  of  FA  with  radiation-
induced proctitis. To our knowledge, there have
been no specific guidelines, or similar reported
experiences, to compare with the present case.
Therefore, we can only speculate that radiation
proctitis could have been avoided if a lower total
dose, or dose/fraction, of brachytherapy had been
used.  Moreover,  although  local  control  was
achieved after a short follow-up period, there was
not enough time for an appropriate rectal treat-
ment to be applied to better evaluate the outcome
of radiation proctitis that developed in associa-
tion with FA. In conclusion, vaginal squamous
cell  carcinoma  in  FA  patients  is  a  rare,  and
always fatal, disease. Currently, there is no con-
clusive evidence to guide the management of
this disease in FA patients, although the results
of this study and others, demonstrates that due to
increased radiosensitivity of these patients, radi-
ation should be used with caution, with doses
kept  below  clinically  recommended  levels.  In
addition,  surgery  should  be  considered  as  an
alternative treatment.
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Figure 1. Magnetic resonance imaging sagittal view showing a vaginal squamous cell car-
cinoma (indicated with arrow) in a patient with FA, prior to (A), and one month after
(B), receiving radiation therapy.
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